[PDF][PDF] Isolated asymptomatic severe neutropenia as the presentation of myeloid/natural killer cell acute leukemia
M Rubio-Batllés, AC de La Mata, M Romero… - …, 2000 - haematologica.org
3. Droll A, Dougherty ST, Chiu RK, et al. Adhesive interactions between alternatively spliced
CD44 isoforms. J Biol Chem 1995; 270: 11567-73. 4. Rafi A, Nagarkatti M, Nagarkatti PS …
CD44 isoforms. J Biol Chem 1995; 270: 11567-73. 4. Rafi A, Nagarkatti M, Nagarkatti PS …
Primary intracranial manifestation of CD7/CD56-positive acute myelogenous leukemia
C Kahl, A Florschütz, K Jentsch-Ullrich… - Oncology Research …, 2000 - karger.com
Background: CD56 which is considered as a marker of natural killer cells is also expressed
in some cases of acute myelogenous leukemia (AML) and is involved in cell adhesion …
in some cases of acute myelogenous leukemia (AML) and is involved in cell adhesion …
Neural Cell Adhesion Molecule (CD56)–Positive Acute Myelogenous Leukemia and Myelodysplastic and Myeloproliferative Syndromes
KP Mann, CM Decastro, J Liu, JO Moore… - American journal of …, 1997 - academic.oup.com
The CD56 antigen is normally expressed on natural-killer cells but has additionally been
shown to be present on a variety of hematologic malignancies, including a subset of acute …
shown to be present on a variety of hematologic malignancies, including a subset of acute …
CD56 expression in myeloperoxidase‐negative FAB M5 acute myeloid leukemia
J Delgado, M Morado, MC Jimenez… - American journal of …, 2002 - Wiley Online Library
CD56 is a natural killer (NK) cell marker that has been identified in approximately 15–20% of
acute myeloid leukemia (AML) cases, where it has been associated with monocytic …
acute myeloid leukemia (AML) cases, where it has been associated with monocytic …
CD56 expression in normal immature granulocytes after allogeneic hematopoietic stem cell transplantation
K Muroi, S Fujiwara, R Tatara, M Sugimoto… - Journal of Clinical and …, 2013 - jstage.jst.go.jp
CD56, a neural cell-adhesion molecule, is expressed in normal NK cells, so the antigen is a
good marker for identifying malignancies in NK cell lineages. 1 CD56 is aberrantly …
good marker for identifying malignancies in NK cell lineages. 1 CD56 is aberrantly …
CD56-positive acute lymphoblastic leukemia
S Matano, S Terahata, S Nakamura, K Kobayashi… - Acta …, 2005 - karger.com
We report a patient with lung cancer who developed CD56-positive acute lymphoblastic
leukemia. He was referred to our hospital for thrombocytopenia. Atypical cells were found in …
leukemia. He was referred to our hospital for thrombocytopenia. Atypical cells were found in …
Labile CD22 and CD19 expression in a case of Philadelphia chromosome-like acute lymphoblastic leukemia
J Mukae, D Sadato, T Toya, S Watanabe… - Leukemia & …, 2022 - Taylor & Francis
Blinatumomab, a bispecific T cell engager antibody against CD19/CD3, and inotuzumab
ozogamicin (InO), an anti-CD22 antibody conjugated to calicheamicin, showed significant …
ozogamicin (InO), an anti-CD22 antibody conjugated to calicheamicin, showed significant …
CD56+/CD4+ lymphomas and leukemias are morphologically, immunophenotypically, cytogenetically, and clinically diverse
CK Rakozy, AN Mohamed, TD Vo… - American journal of …, 2001 - academic.oup.com
CD56, a neural adhesion molecule, is a marker of natural killer (NK) lymphocytes as well as
a subgroup of CD8+ T cells. Normal lymphocytes with a CD56/CD4 phenotype are scarce …
a subgroup of CD8+ T cells. Normal lymphocytes with a CD56/CD4 phenotype are scarce …
Chronic myelomonocytic leukemia derived from a possible common progenitor of monocytes and natural killer cells
H Kojima, A Bai, H Mukai, M Hori, T Komeno… - Leukemia & …, 2000 - Taylor & Francis
The neural cell adhesion molecule, CD56, is expressed on acute myelogenous leukemia
(AML) cells in 17–20% of the patients. However, the clinical and biological significance of its …
(AML) cells in 17–20% of the patients. However, the clinical and biological significance of its …
Aberrant expression of CD5 in adult acute myeloid leukemia belonged to AML-MR, may represent a uniquely aggressive subcategory
Y Zhang, Y Ding, R Zhang, L Zhang, X Yan… - Leukemia & …, 2023 - Taylor & Francis
According to 2022 Who [5], AML myelodysplasia-related (AML-Mr) is defined as a neoplasm
with≥ 20% blasts expressing a myeloid immunophenotype and harboring specific …
with≥ 20% blasts expressing a myeloid immunophenotype and harboring specific …